National Association of Testing Authorities, Australia
Scope of Accreditation
Pathology Queensland
Site
Central Laboratory
Accreditation No.
2639
Site No.
2632
Date of Accreditation
05 Dec 1986
Address
ROYAL BRISBANE AND WOMEN'S HOSPITAL, Level 4, Block 7, 40 Butterfield St
Herston, QLD 4006
Australia
Contact
Ms Mary Hardwick P: +61 (07) 36367847
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Anatomical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical smear; Cervical tissue; Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Endometrial pipelle; Liquid based cytology specimens from cervix; Vaginal smears; Vaginal tissue; Vault smears; Vulval smears | Cytological examination; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Aspirates; Bronchial lavage; Cerebrospinal fluid (CSF); Ocular specimens; Other body fluids; Sputum; Tumour tissue; Urine; Vitreous specimens; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Anus smears; Lip smears; Mouth smears; Nipple discharge; Nose smears; Semen; Skin smears | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Tissue pathology - Analysis of molecular targets in tissue samples other than by in situ hybridisation | Formalin-fixed paraffin-embedded (FFPE) tissues | Cytokeratin19 mRNA in sentinel nodes |
| Ploidy studies | ||
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue; Smears | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Examination of biopsy material by electron microscopy | Fluids; Formalin-fixed tissue; Fresh tissue; Gluteraldehyde tissue; Hair; Leucocyte (leukocyte) buffy coat; Nasal brushings; Platelets; Smears | Review and reporting of biopsy material to identify or exclude ultra-structural morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin fluorescence in situ hybridisation (FISH) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Detection of nucleic acid targets - Various | ||
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Detection of nucleic acid targets - Various | ||
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue; Smears; Tissue imprint | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Formalin-fixed paraffin-embedded (FFPE) tissues; Frozen tissue | Detection of antigenic targets - Various |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Fixed cytological smears; Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen sections of fresh tissue | Detection of antigenic targets - Various |
| Detection of antigenic targets - Various | ||
| Anatomical pathology - Tissue pathology - Mortuary facilities | Body; Body parts | Assessment - Level 3 mortuary |
| Anatomical pathology - Tissue pathology - Non-coronial autopsy services | Body; Body parts | Autopsy service and reporting |
| Anatomical pathology - Tissue pathology - Skeletal muscle enzyme histochemistry | Frozen sections of skeletal muscle | Detection of muscle enzyme targets |
Chemical Pathology
ISO 15189 (2012)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Other body fluids; Plasma; Serum | Detection and quantitation of free kappa and free lambda light chains |
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of calculus | Calculi; Renal calculi | Ammonium; Apatite; Bilirubin; Calcium; Calcium oxalate dihydrate (weddelite); Calcium oxalate monohydrate; Carbonate; Cholesterol; Cysteine; Magnesium; Oxalate; Phosphate; Silicon; Sulfate; Triple phosphate - Struvite; Urate; Uric acid; Xanthine |
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Gastric aspirate; Urine | 2-Ethyl-5-methyl-3,3-diphenylpyrrolidine (EMDP); 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); 6-Acetylmorphine; 6:2 Fluorotelomer sulfonate (6:2 FTS); 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Alprazolam; Amphetamines; Barbiturates; Benzodiazepines; Benzoylecgonine (ecgonine benzoate); Benzylpiperazine (BZP, 1-benzylpiperazine); Bromazepam; Buprenorphine; Caffeine; Cannabis; Clobazam; Cocaine; Diazepam; Ecgonine methyl ester; Ephedrine; Ethylglucuronide (ETG); Fentanyl; Flunitrazepam; Ketamine; Lysergic acid diethylamide (LSD, lysergide); Methadone; Methadone metabolites; Methamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Nitrazepam; Nordiazepam; Opiates; Oxazepam; Oxycodone; Oxymorphone; Paraquat; Perfluorobutane sulfonate (PFBS); Perfluorodecanoic acid (PFDA); Perfluoroheptanoic acid (PFHpA); Perfluorohexane sulfonate (PFHxS); Perfluorohexanoic acid (PFHxA); Perfluorononanoic acid (PFNA); Perfluorooctane sulfonic acid (PFOS); Perfluorooctanoic acid (PFOA); Phencyclidine; Phentermine; Propoxyphene; Pseudoephedrine (PSE); Salbutamol; Sulfonylurea; Sympathomimetic amines; Synthetic cannabis; Temazepam; Tramadol; α-Hydroxyalprazolam |
| Plasma; Serum | Acetone; Ethanol; Ethyleneglycol (monoethylene glycol, MEG); Methanol; Propan-2-ol (isopropyl alcohol, isopropanol, 2-propanol); Propylene (propene) glycol | |
| Thiocyanate | ||
| Ethanol; Paracetamol (acetaminophen); Salicylate | ||
| Urine | Amphetamines; Benzodiazepines | |
| Buprenorphine; Cannabis; Cocaine; Methadone; Opiates | ||
| Cotinine; Nicotine | ||
| Chemical pathology - Biogenic amines | Blood | Serotonin |
| Cerebrospinal fluid (CSF) | 5-Hydroxyindoleacetic acid (5-HIAA); Homovanillic acid (HVA); Methyldopa; Neopterin; Tetrahydrobiopterin | |
| Plasma; Serum | Adrenaline; Dopamine; Noradrenaline | |
| Plasma; Serum; Urine | Metadrenaline; Methoxytyramine; Normetadrenaline | |
| Urine | Adrenaline; Dopamine; Noradrenaline | |
| 4-Hydroxy-3-methoxymethamphetamine (HMMA); 5-Hydroxyindoleacetic acid (5-HIAA); Homovanillic acid (HVA) | ||
| Primapterin | ||
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | 6-Methylmercatopurine (6MMP); 6-Thioguanine |
| Cyclosporin; Everolimus; Sirolimus; Tacrolimus | ||
| Plasma | Amoxicillin; Ampicillin; Benzylpenicillin; Cefazolin; Cefepime; Ceftazidime; Ceftolozane; Ceftriaxone; Cephalothin; Clobazam; Clonazepam; Clozapine; Ertapenem; Flucloxacillin; Meropenem; Norclozapine; Piperacillin; Tazobactam | |
| Busulfan | ||
| Mycophenolate | ||
| Amitriptyline; Clomipramine; Desipramine; Dothiepin (dosulepin); Doxepin; Imipramine; Mianserin; Nortriptyline; Olanzapine; Trimipramine | ||
| Plasma; Serum | Acetyl isoniazid; Azithromycin; Bedaquiline; Cefoxitin; Clarithromycin; Clofazimine; Cycloserine; Delamanid; Ethambutol; Faropenem; Isoniazid; Linezolid; Pretomanid; Pyrazinamide; Ribabutin; Rifampicin; Rifapentine; Tedizolid; Tigecycline | |
| 5-Flucytosine; Acyclovir; Amphotericin; Amprenavir; Busulfan; Carbamazepine epoxide; Ceftazidime; Efavirenz; Ganciclovir; Hydroxyperhexiline (OH-perhexiline); Indinavir; Ivermectin; Leflunamide; Leflunamide metabolite (teriflunamide); Lopinavir; Mycophenolate; Nelfinavir; Nevirapine; Norclobazam; Perhexiline; Phenobarbitone; Saquinavir; Streptomycin; Sulfonylurea; Teicoplanin; Thiopentone; Ubiquinone; Warfarin | ||
| 9-Hydroxyrisperidone; Aripiprazole; Chlorpromazine; Dehydro aripiperazole; Flupentixol; Haloperidol; Olanzapine; Risperidone; Zuclopenthixol | ||
| 10-Hydroxycarbazepine; Brivaracetam; Carbamazepine; Lacosamide; Lamotrigine; Levetiracetam; Perampanel; Phenytoin (dilantin); Topiramate; Valproate (valproic acid, epilim); Zonisamide | ||
| Elexacaftor; Hydroxymethyl ivacaftor; Ivacaftor; Ivacaftor carboxylic acid; Lumacaftor; Tezacaftor; Tezacaftor metabolite M1 | ||
| Asparaginase | ||
| Amikacin; Carbamazepine; Digoxin; Gentamicin (cidomycin, septopal, genticyn, garamycin); Pentobarbitone; Phenytoin (dilantin); Theophylline; Tobramycin; Valproate (valproic acid, epilim); Vancomycin | ||
| Ciproflocaxin; Levofloxacin; Moxifloxacin | ||
| Amiodarone; Bupivacaine; Desethylamiodarone; Ethosuximide; Flecainide; Glycinexylidide (GX); Lamotrigine; Levetiracetam; Lignocaine; Mexiletine; Monoethylglycinexylidide (MEGX); Ropivacaine; Sotalol | ||
| Methotrexate | ||
| 5-Flucytosine; Fluconazole; Hydroxyitraconazole; Itraconazole; Posaconazole; Voriconazole | ||
| Infliximab | ||
| Ethosuximide | ||
| Serum | Lithium | |
| Urine | Bisacodyl - Cathartic; Danthron - Cathartic; Phenolphthalein - Cathartic; Rhein - Cathartic | |
| Chemical pathology - Detection and/or quantitation of tumour markers | Ascitic fluid; Pleural fluid | CA19-9 antigen (CA19-9) |
| CA125 antigen (CA125); Carcinoembryonic antigen (CEA); α-Fetoprotein (AFP) | ||
| Human chorionic gonadotropin (hCG) | ||
| Cerebrospinal fluid (CSF); Serum | Neuron specific enolase (NSE) | |
| Peritoneal dialysis fluid | CA125 antigen (CA125) | |
| Plasma; Serum | CA125 antigen (CA125); Carcinoembryonic antigen (CEA); Prostate specific antigen (PSA); α-Fetoprotein (AFP) | |
| Anti-thyroglobulin; Thyroglobulin | ||
| Chromogranin A - Gen I | ||
| Human chorionic gonadotropin (hCG) | ||
| CA125 antigen (CA125); Human epididymal protein 4ROMA calculation | ||
| CA15-3 antigen (CA15-3) | ||
| CA19-9 antigen (CA19-9) | ||
| Plasma; Serum; Urine | β2-Microglobulin (B2M) | |
| Serum | Free β-human chorionic gonadotropin (free β-hCG) | |
| Chemical pathology - Detection of faecal occult blood | Faeces | Haemoglobin (Hb) |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Adrenocorticotropic hormone (ACTH) |
| C-peptide; Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| Renin | ||
| Plasma; Serum | 11-Deoxycorticosterone; 11-Deoxycortisol; 17α-Hydroxyprogesterone; 21-Deoxycortisol; Androstenedione; Corticosterone; Cortisol; Cortisone; Dehydroepiandrosterone (DHEA); Dehydroepiandrosterone sulfate (DHEAS); Dexamethasone; Dihydrotestosterone; Prednisolone; Progesterone; Testosterone; Testosterone - Free | |
| Macroprolactin | ||
| Aldosterone | ||
| Dehydroepiandrosterone sulfate (DHEAS); Growth hormone; Sex hormone binding globulin (SHBG) | ||
| Procalcitonin | ||
| Copeptin | ||
| Oestradiol; Oestrone | ||
| Cortisol | ||
| Follicle stimulating hormone (FSH); Insulin; Luteinising hormone (LH); Parathyroid hormone (PTH); Progesterone; Prolactin | ||
| Cortisol - Free; Cortisone - Free; Prednisolone - Free | ||
| 21-Deoxycortisol; Prednisolone | ||
| Saliva; Urine | Cortisol; Cortisone; Prednisolone | |
| Serum | Gastrin | |
| Urine | Aldosterone | |
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Plasma; Serum | Fructosamine | |
| Chemical pathology - Dynamic tests | Sweat | Sweat chloride |
| Chemical pathology - Further investigation of cardiac function | Ascitic fluid; Pleural fluid | B-type natriuretic peptide (BNP) |
| Blood; Plasma | Troponin I | |
| Plasma | B-type natriuretic peptide (BNP) | |
| Plasma; Serum | Troponin I | |
| N-Terminal-pro b-type natriuretic peptide (NT-proBNP) | ||
| Troponin I | ||
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | Lipoprotein subclasses |
| HDL - Quantitation | ||
| Lipoprotein a | ||
| Apolipoprotein A1; Apolipoprotein B | ||
| Chemical pathology - Further investigation of renal and/or hepatic function | Faeces | α1-Antitrypsin |
| Other body fluids; Serum | Bile acids - Quantitative | |
| Plasma | Fibroblast growth factor 23 (FGF23) | |
| Plasma; Serum | α1-Antitrypsin phenotype | |
| Caeruloplasmin; Prealbumin; α1-Antitrypsin | ||
| Caeruloplasmin activity | ||
| Haptoglobins | ||
| Plasma; Serum; Urine | Iohexol | |
| Chemical pathology - Haem related pigments and precursors (excluding porphyria) | Cerebrospinal fluid (CSF) | Bilirubin; Oxyhaemoglobin |
| Plasma | Haemoglobin (Hb) | |
| Plasma; Serum | Myoglobin | |
| Urine | Bilirubin | |
| Haemoglobin (Hb) | ||
| Myoglobin | ||
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Amniotic fluid | Acetylcholinesterase (RCAC) |
| Ascitic fluid; Pleural fluid | Alanine aminotransferase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin - Total; Calcium - Total; Chloride; Cholesterol - Total; Glucose; Lactate; Lactate dehydrogenase (LDH); Lipase; Magnesium; Potassium; Protein - Total; Sodium; Triglycerides; γ-Glutamyltransferase | |
| Blood | Creatinine; Glucose | |
| Cytochrome B5 reductase | ||
| Blood; Dried blood spots | Phosphatidylethanol (PEth) | |
| Cerebrospinal fluid (CSF) | Lactate dehydrogenase (LDH) | |
| Glucose; Lactate; Protein - Total | ||
| AlbuminLow level | ||
| Cerebrospinal fluid (CSF); Other body fluids; Plasma; Serum | Adenosine deaminase | |
| Cerebrospinal fluid (CSF); Plasma; Serum | Angiotensin converting enzyme (ACE)ACE mass assay. | |
| Erythrocytes (red blood cells, RBC) | Acetylcholinesterase (RCAC) | |
| Faeces | Bicarbonate; Chloride; Magnesium; Potassium; Sodium | |
| Other body fluids; Plasma; Serum; Urine | Osmolality | |
| Peritoneal dialysis fluid | Calcium - Total; Chloride; Cholesterol - Total; Creatinine; Glucose; Lipase; Magnesium; Potassium; Sodium; Triglycerides; Urea | |
| Plasma | Ammonia; Lactate | |
| Plasma; Serum | Bilirubin - Total; Calcium - Ionised; Chloride; Glucose; Lactate; Potassium; Sodium | |
| Chloride; Potassium; Sodium | ||
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Protein - Total; Triglycerides; Urate; Urea; γ-Glutamyltransferase | ||
| Adenosine deaminase isoenzymes | ||
| Asparaginase; Cholinesterase; Cholinesterase panel - Fluoride number; Cystatin C; Dibucaine (cinchocaine) | ||
| Pleural fluid | pH | |
| Urine | Chloride; Potassium; Sodium | |
| Ammonia; Bicarbonate | ||
| Urobilinogen | ||
| Glucose | ||
| Albumin; Amylase; Calcium - Total; Chloride; Creatinine; Glucose; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | ||
| Chemical pathology - Investigation for folate deficiency | Serum | Folate |
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C14 |
| Chemical pathology - Investigation of functional intestinal disorders | Breath | Carbon dioxide (CO2); Hydrogen/methane |
| Chemical pathology - Investigation of malabsorption | Faeces; Urine | Reducing substances |
| Chemical pathology - Investigation of malabsorption - Quantitation of solid tissue enzymes | Intestinal tissue | Alkaline phosphatase; Lactase; Maltase; Protein - Microsomal triglyceride transfer (MTP); Sucrase |
| Chemical pathology - Investigation of maternal markers for pre-eclampsia | Plasma; Serum | FMS-like tyrosine kinase 1 - Soluble; Placental growth factor (PGF, PLGF) |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Amniotic fluid; Plasma; Serum | α-Fetoprotein (AFP) |
| Serum | Pregnancy associated plasma protein A (PAPP-A) | |
| Chemical pathology - Investigation of porphyria | Blood; Faeces | Porphyrin isomers; Porphyrins - Total; Protoporphyrin |
| Plasma | Porphyrins - Total | |
| Urine | Porphobilinogen (PBG); Porphyrin isomers; Porphyrins - Total | |
| δ-Aminolevulinic acid (δ-ALA) | ||
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin; Iron; Transferrin |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Anion gap; Base excess; Bicarbonate; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; p50; pH |
| Base excess; Bicarbonate; Calcium - Ionised; Glucose; Haematocrit (packed cell volume, PCV); Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; Total carbon dioxide (TCO2); Total haemoglobin - Calculated; pH | ||
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Blood; Cerebrospinal fluid (CSF) | Pyruvate |
| Plasma; Serum | β-Hydroxybutyrate | |
| Urine | Amino acids | |
| Acetoacetate | ||
| Citrate; Oxalate | ||
| Chemical pathology - Quantitation of vitamins | Blood | Pyridoxine (vitamin B6, pyridoxal, pyridoxamine); Thiamine (vitamin B1) |
| Blood; Plasma; Serum | Carotenoids; Retinol (vitamin A); Retinyl palmitate; Tocopherol (vitamin E) | |
| Plasma; Serum | 1,25-Dihydroxyvitamin D | |
| 25-Hydroxyvitamin D | ||
| Cobalamin (vitamin B12) | ||
| Serum | Ascorbic acid (vitamin C) | |
| Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Chemical pathology - Trace element analysis | Blood | Arsenic; Cadmium; Chromium; Cobalt; Lead; Manganese; Mercury |
| Liver | Copper; Iron | |
| Plasma; Serum | Aluminium; Chromium; Cobalt; Copper; Selenium; Zinc | |
| Urine | Arsenic; Cadmium; Chromium; Copper; Iodine; Lead; Mercury; Zinc | |
| Haematology - Limited blood examination | Plasma | Viscosity |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma; Serum | Anti-thyrotropin receptor antibodies (TSHR) |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Cerebrospinal fluid (CSF); Other body fluids; Serum | β-Trace protein (β-TP) |
| Cerebrospinal fluid (CSF); Plasma; Serum | Oligoclonal bands | |
| Faeces | Calprotectin | |
| Pancreatic elastase | ||
| Plasma; Serum | Thyroxine binding globulin | |
| Retinol binding protein; Soluble transferrin receptor (sTFR) | ||
| Cryofibrinogen; Cryoglobulins | ||
| Albumin; α1-Globulin; α2-Globulin; β-Globulin; γ-Globulin | ||
| Serum | Alkaline phosphatase (ALP) isoenzymes; Creatine kinase (CK) isoenzymes; Lactate dehydrogenase (LDH) isoenzymes | |
| Urine | Albumin; α1-Globulin; α2-Globulin; β-Globulin; γ-Globulin | |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Cerebrospinal fluid (CSF) | Total immunoglobulin G |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Serum; Urine | Human chorionic gonadotropin (hCG) |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Plasma; Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
| Human chorionic gonadotropin (hCG) - Quantitative total | ||
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Faeces | Helicobacter pylori |
Chemical Pathology – Biochemical Genetics and Newborn screening
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Biochemical genetic services - Amino acid quantitation | Cerebrospinal fluid (CSF) | Alanine; Arginine; Glutamine; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Ornithine; Phenylalanine; Serine; Taurine; Threonine; Tyrosine; Valine |
| Dried blood spots; Plasma; Urine | 1-Methylhistidine; 3-Methylhistidine; Alanine; Alloisoleucine; Arginine; Arginosuccinic acid; Asparagine; Aspartic acid; Carnosine; Citrulline; Cystathionine; Cystine; Glutamic acid; Glutamine; Glycine; Histidine; Homocysteine; Hydroxyproline; Isoleucine; Leucine; Lysine; Methionine; Ornithine; Phenylalanine; Phosphoethanolamine; Phosphoserine; Proline; Sarcosine; Serine; Taurine; Threonine; Tryptophan; Tyrosine; Valine; α-Aminoadipic acid; α-Aminobutyric acid; β-Alanine; γ-Aminobutyric acid | |
| Chemical pathology - Biochemical genetic services for the diagnosis of metabolic and enzymological disorders | Amniotic fluid; Plasma; Serum | 7-Dehydrocholesterol; 8-Dehydrocholesterol; Cholest-8(9)-enol; Cholestanol; Stigmasterol; γ-Hydroxybutyric acid (GHB) |
| Blood | Porphobilinogen synthase | |
| Thiopurine methyltransferase (TPMT) | ||
| Erythrocytes (red blood cells, RBC) | Glutathione peroxidase | |
| Adenosine deaminase; Hypoxanthine phosphoribosyl transferase; Purine nucleoside phosphorylase | ||
| Gal-1-p-uridyl transferase | ||
| Leucocytes (leukocytes) | Hypoxanthine phosphoribosyl transferase; Phosphomannomutase profile; Thymidine phosphorylase | |
| Leucocytes (leukocytes); Plasma | Lysosomal profile | |
| Plasma | Methylmalonic acid (MMA) | |
| Chitotriosidase | ||
| Plasma; Serum | Biotinidase | |
| Very long chain fatty acids (vLCFA) | ||
| Acylcarnitine profile; Carnitine - Free; Carnitine uptake; Carnitines | ||
| Carbohydrate deficient transferrin; Transferrin isoforms | ||
| Pyroglutamate | ||
| Homocysteine | ||
| Plasma; Serum; Urine | D-lactate | |
| Glycerol | ||
| Urine | n-Acetylneuraminidase | |
| Sulfite | ||
| Glycosaminoglycans (MPS); Mucopolysaccharides (MPS) | ||
| Succinylaminoimidazolecarboxamide ribose-5′-phosphate (SAICAR) | ||
| Trimethylamine; Trimethylamine-n-oxide | ||
| Organic acids | ||
| Oligosaccharides | ||
| Chemical pathology - Newborn screening services for the diagnosis of inborn errors of metabolism | Dried blood spots | Gal-1-p-uridyl transferase |
| 17-Hydroxyprogesterone; Thyroid stimulating hormone (TSH) | ||
| Carnitines; Citrulline; Homocysteine; Leucine; Methionine; Phenylalanine; Tyrosine | ||
| Galactose; Galactose-1-phosphate | ||
| Immunoreactive trypsin | ||
| 11-Deoxycortisol; 17-Hydroxyprogesterone; 21-Deoxycortisol; Androstenedione; Cortisol | ||
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted panels for inherited (germline) DNA/RNA changes | Dried blood spots | Severe combined immunodeficiency disease (SCID); Spinal muscular atrophy |
Cytogenetics
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in situ hybridisation techniques | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Lymph nodes; Products of conception (POC); Tumour imprints | Cytogenetic analysis and reporting |
| Cytogenetics - Karyotype detection of balanced and/or unbalanced chromosome abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Fixed cell pellets; Other tissues - Malignant; Other tissues - Non-malignant; Products of conception (POC) | Acquired genetic abnormalities; Constitutional genetic abnormalities |
| Blood; Saliva | Constitutional genetic abnormalities | |
| Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities | Amniotic fluid; Blood; Bone marrow; Chorionic villus tissue; Lymph nodes; Other tissues - Malignant; Other tissues - Non-malignant; Products of conception (POC) | Cytogenetic analysis and reporting |
| Molecular genetics - Heterozygous loci determinations | Tissues | Aneuploidy screening; Polymorphic short tandem repeat (STR) marker genotype analysis |
| Molecular genetics - Screening for an unknown mutation - Microarray analysis for inherited (germline) DNA/RNA changes | Blood | Charcot-Marie-Tooth neuropathy; Copy number variation (CNV); Duchenne-Becker muscular dystrophy; Hereditary neuropathy with liability to pressure palsies |
| Molecular genetics - Screening for an unknown mutation - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood; Bone marrow | Haematological malignancies |
| Haematological malignancies |
Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Blood; Other body fluids; Plasma; Serum; Snake bite site; Swabs; Tissues; Urine | Snake venom detection |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Serum | Erythropoietin (EPO) |
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Bone marrow examination | Bone marrow; Trephine | Examination of aspirated material; Histological examination |
| Haematology - Diagnosis of thalassemia | Blood | Examination of haemoglobin H (HbH); Haemoglobin A (HbA) - Quantitation; Haemoglobin A2 (HbA2) - Quantitation |
| Blood; Plasma; Serum | Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation | |
| Haematology - Examination of blood films by special staining | Blood | Haemoglobin H; Heinz bodies |
| Cerebrospinal fluid (CSF) | Morphology | |
| Haematology - Examination of blood films by special stainingState Reference Laboratory | Blood | Malaria |
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Feto-maternal haemorrhage (FMH) estimation |
| Detection and quantitation of foetal red cell antigens | ||
| Feto-maternal haemorrhage (FMH) estimation | ||
| Blood; Faeces; Gastric aspirate; Vomitus | Detection and quantitation of foetal red cells | |
| Haematology - Full blood examination | Blood | Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Platelet count; Red blood cell index or indices |
| Differential number; Morphology | ||
| Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Kaolin clotting time |
| Platelet aggregation | ||
| International normalised ratio (INR) | ||
| Platelet function (PFA) | ||
| Plasma | Echis test | |
| Heparin induced thrombotic thrombocytopenia (HITT) | ||
| Von Willebrand collagen binding assay; Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Activated partial thromboplastin time (APTT); International normalised ratio (INR); Prothrombin time (PT) | ||
| Von Willebrand factor (vWF) multimers | ||
| Activated protein C (APC) resistance; Anti-Xa - Apixaban; Anti-Xa - Rivaroxaban; Anti-Xa activity - Unfractionated heparin; Anti-thrombin III; D-dimer; Factor II; Factor IX; Factor V; Factor VII; Factor VIII; Factor X; Factor XI; Factor XII; Fibrinogen degradation products; Heparin assay; Plasminogen; Protein C and protein S; Thrombin anti-thrombin complex (TAT); Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | ||
| Factor VIII | ||
| Anti-Xa - Fondaparinux; Anti-Xa - Orgaran; Clauss fibrinogen; Factor IX inhibitor; Factor VIII inhibitor; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Mixing studies - APTT; Prothrombin time (PT); Prothrombin time (PT) mixing studies; Reptilase time | ||
| APTT heparin neutralisation; Activated partial thromboplastin time (APTT); Mixing studies - APTT; Thrombin time (TT) | ||
| Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Other abnormal haemoglobins |
| Haemoglobin instability | ||
| Haemoglobin fraction (S, C, D, E) - Quantitation | ||
| Haemoglobin S (HbS) - Presence | ||
| Haematology - Investigation of haemolysis | Blood | Cold agglutinins |
| Plasma | Von Willebrand factor cleaving protease (vWFCP) | |
| Serum | Donath-Landsteiner antibody | |
| Urine | Haemosiderin | |
| Haematology - Limited blood examination | Blood | Haemoglobin (Hb) |
| Erythrocyte (RBC) sedimentation rate (ESR) | ||
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-intrinsic factor antibodies (IF) |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Plasma | Fibrinogen - Immunological |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Blood | Plasmodium spp. |
| Microbiology - Parasitology - Detection of ova, cysts and parasitesState Reference Laboratory | Blood | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Plasma; Serum | Infectious mononucleosis |
ID Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Blood; Bone marrow; Cerebrospinal fluid (CSF); Fluids; Plasma; Serum; Tissues | Brucella spp. |
| Blood; Bone marrow; Cerebrospinal fluid (CSF); Formalin-fixed paraffin-embedded (FFPE) tissues; Placenta; Respiratory specimens; Serum; Tissues | Coxiella burnetti | |
| Blood; Cerebrospinal fluid (CSF); Serum | Kingella kingae | |
| Blood; Dry swabs; Skin swabs; Tissues; Wound swabs | Orientia tsutsugamushi (scrub typhus); Rickettsia spp. | |
| Endocervical swabs; Eye swabs; Meatal swabs; Oropharyngeal swabs; Rectal swabs; Urethral swabs; Urine; Vaginal swabs | Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae | |
| Faeces | Aeromonas spp.; Campylobacter spp.; Clostridium difficile toxin B; Escherichia coli - Enteroinvasive (EIEC); Salmonella spp.; Shigella spp.; Vibrio spp.; Yersinia enterocolitica | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Endocervical swabs; Meatal swabs; Oropharyngeal swabs; Rectal swabs; Urethral swabs; Urine; Vaginal swabs | Trichomonas vaginalis |
| Faeces | Blastocystis hominis; Cryptosporidium spp.; Cyclospora cayetanensis; Dientamoeba fragilis; Entamoeba histolytica; Giardia lamblia | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Blood; Cerebrospinal fluid (CSF); Serum | Japanese encephalitis virus (JEV) |
| Endotrachael aspirate; Nasopharyngeal swabs; Oropharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | |
| Faeces | Adenovirus F40; Adenovirus F41; Astrovirus; Norovirus G1; Norovirus G2; Rotavirus A; Sapovirus I; Sapovirus II; Sapovirus IV; Sapovirus V | |
| Genital swabs; Mouth swabs; Skin lesions | Orthopox virus group | |
| Nasal aspirates/washes; Nasopharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | ||
| Nasal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | ||
| Nasopharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | |
| Nasopharyngeal swabs; Oropharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) - PCR, RT-PCR | ||
| Microbiology - Molecular biology - Surveillance programme for the detection of microbial nucleic acids (viruses) in accordance with Commonwealth and/or State Health protocols | Saliva | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
| Saliva suck swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
Immunology – Core Chemistry
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Serum | C1 esterase inhibitor |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Rheumatoid factor |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicillin; Penicilloyl G; Penicilloyl V |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Budgerigar feathers; Canary bird feathers; Cat dander; Cat epithelium; Chicken feathers; Cow dander; Dog dander; Duck feathers; Finch feathers; Goose feathers; Guinea pig epithelium; Hamster epithelium; Horse dander; Mouse epithelium; Mouse serum proteins; Mouse urine proteins; Parakeet feathers; Parrot feathers; Rabbit epithelium; Rat epithelium; Rat serum proteins; Rat urine proteins; Turkey feathers |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg; Egg white; Egg yolk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Lobster; Oyster; Shrimp; Squid; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fruit and vegetable] allergens) | Serum | Apple; Avocado; Banana; Capsicum; Cherry; Green olive; Kiwi; Mango; Olive - Black, fresh; Onion; Orange citrus; Peach; Pineapple; Plum; Potato; Pumpkin; Tomato |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Lamb; Pork |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Cheese - Cheddar type; Milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Chocolate; Yeasts |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Buck wheat; Cashew nut; Coconut; Corn; Gluten; Hazelnut; Macadamia nut; Oat; Peanut; Pecan nut; Pistachio; Poppy seed; Rice; Rye; Sesame seed; Soy bean; Walnut; Wheat |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Bermuda grass; Johnson grass; Kentucky plane (June) grass; Rye grass; Timothy grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | Fire ant; German cockroach; Mosquito; Oriental cockroach |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Alternaria tenius; Anisakis; Aspergillus fumigatus; Candida albicans; Cladosporium herbarum; Penicillium chrysogenum (formerly Penicillium notatum) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite; House dust - Greer; House dust - Hollister-Stier |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Latex; Sunflower seed |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Australian pine; Eucalyptus; Melaleuca; Olive; White pine; Willow salix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | European hornet venom; Honey bee venom; Paper wasp venom; Yellow hornet venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Common ragweed; Lamb’s quarters; Mugwort; Plantain - English; Rapeseed; Russian thistle |
| Immunopathology - Quantitation of complement proteins | Plasma; Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Plasma; Serum | Immunoglobulin subclasses; Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M |
| Serum | Total immunoglobulin E | |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Serum | Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies |
Immunopathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Serum | C1 esterase inhibitor |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Aspirates; Blood; Bone marrow; Cerebrospinal fluid (CSF); Disaggregated tissues specimen; Fresh tissue; Lavage | AML Minimal residual disease (MRD) |
| B-ALL/COG Minimal residual disease (MRD) | ||
| Aspirates; Cerebrospinal fluid (CSF); Disaggregated tissues specimen; Fresh tissue; Lavage | Anti-CD154; Anti-glycophorin A (GLYA); Anti-human CD127; Assessment of lymphoid cell populations; Assessment of myeloid cell populations; B-cell; CD10; CD103; CD117; CD11a; CD11b; CD11c; CD123; CD13; CD138; CD14; CD15; CD16; CD18; CD19; CD1a; CD2; CD20; CD200; CD21; CD22; CD23; CD25; CD26; CD27; CD3; CD30; CD303; CD33; CD34; CD38; CD4; CD40; CD41; CD43; CD44; CD45; CD45RA; CD45RO; CD5; CD56; CD57; CD58; CD61; CD64; CD65; CD66c; CD69; CD7; CD71; CD79a; CD79b; CD8; CD81; CD9; CD99; FMC7; HLA-DR antigen; Immunoglobulin A (IgA) specific for α-chains; Immunoglobulin D (IgD); Immunoglobulin G (IgG); Immunoglobulin G1 (IgG1); Immunoglobulin M (IgM); Kappa light chains; Lambda light chains; Myeloperoxidase; Neuron-glial antigen 2 (NG2); Perforin; T-cell receptor Cβ1 (TCRJOVI-1); T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT) | |
| Blood | Signalling lymphocytic activation molecule (SLAM)-associated protein (SAP); X-linked inhibitor of apoptosis protein (XIAP) | |
| Anti-Bruton's tyrosine kinase (BTK); Anti-CD154; Anti-glycophorin A (GLYA); Anti-human CD127; Assessment of lymphoid cell populations; Assessment of myeloid cell populations; CD10; CD103; CD117; CD11a; CD11b; CD11c; CD123; CD13; CD138; CD14; CD15; CD16; CD18; CD19; CD1a; CD2; CD20; CD200; CD21; CD22; CD23; CD25; CD26; CD27; CD3; CD30; CD303; CD33; CD34; CD38; CD4; CD40; CD40 ligand; CD41; CD43; CD44; CD45; CD45RA; CD45RO; CD5; CD56; CD57; CD58; CD61; CD64; CD65; CD66c; CD69; CD7; CD71; CD79a; CD79b; CD8; CD81; CD9; CD99; FMC7; HLA-DR antigen; Immunoglobulin A (IgA) specific for α-chains; Immunoglobulin D (IgD); Immunoglobulin G (IgG); Immunoglobulin G1 (IgG1); Immunoglobulin M (IgM); Kappa light chains; Lambda light chains; Memory cells; Myeloperoxidase; Neuron-glial antigen 2 (NG2); Perforin; T reg cells; T-cell receptor Cβ1 (TCRJOVI-1); T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT); Wiscott-Aldrich syndrome protein (WASp) | ||
| Blood; Bone marrow | CLL Minimal residual disease (MRD) | |
| Blood; Bone marrow; Fluids; Fresh tissue | T-cell receptor Cβ1 (TCRJOVI-1) | |
| Bone marrow | Anti-glycophorin A (GLYA); Anti-human CD127; Assessment of lymphoid cell populations; Assessment of myeloid cell populations; CD10; CD103; CD117; CD11a; CD11b; CD11c; CD123; CD13; CD138; CD14; CD15; CD16; CD18; CD19; CD1a; CD2; CD20; CD200; CD21; CD22; CD23; CD25; CD26; CD27; CD3; CD30; CD303; CD33; CD34; CD38; CD4; CD40; CD41; CD43; CD44; CD45; CD5; CD56; CD57; CD58; CD61; CD64; CD65; CD66c; CD69; CD7; CD71; CD79a; CD79b; CD8; CD81; CD9; CD99; FMC7; HLA-DR antigen; Immunoglobulin A (IgA) specific for α-chains; Immunoglobulin D (IgD); Immunoglobulin G (IgG); Immunoglobulin G1 (IgG1); Immunoglobulin M (IgM); Kappa light chains; Lambda light chains; Myeloperoxidase; Neuron-glial antigen 2 (NG2); Perforin; T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT) | |
| Immunopathology - Complete HLA antigen tissue typing | Blood | Crossmatch for transplant recipients |
| HLA class I antigens; HLA-A, HLA-B class I antigens; HLA-C class I antigens | ||
| HLA class I antibodies; HLA class II antibodies | ||
| Crossmatch for transplant recipients | ||
| Extracted DNA | HLA class I antigens; HLA class II antigens; HLA-A, HLA-B class I antigens; HLA-C class I antigens; HLA-DR, HLA-DP, HLA-DQ class II antigens | |
| HLA class I antigens; HLA class II antigens; HLA-A, HLA-B class I antigens; HLA-C class I antigens; HLA-DR, HLA-DP, HLA-DQ class II antigens | ||
| HLA class I antigens; HLA class II antigens; HLA-A, HLA-B class I antigens; HLA-C class I antigens; HLA-DR, HLA-DP, HLA-DQ class II antigens | ||
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Cerebrospinal fluid (CSF); Other body fluids; Serum | Anti-nuclear antibodies (ANA) |
| Cerebrospinal fluid (CSF); Serum | Anti-GQ1b IgG antibody; Anti-ganglioside antibodies | |
| Anti-glutamic acid decarboxylase antibodies (GAD); Anti-neuronal antibodies | ||
| Anti-IgLON5 antibodies; Anti-N-methyl-D-aspartate receptor antibodies (NMDA); Anti-dipeptidyl aminopeptidase-like protein 6 antibodies (DPPX); Anti-gamma aminobutyric acid (GABA) B receptor antibodies; Anti-glutamate receptor antibodies (AMPA/NMDA); Anti-myelin oligodendrocyte glycoprotein antibodies (MOG); Anti-voltage gated potassium channel complex antibodies (VGKC) | ||
| Anti-neuromyelitis optica antibodies (NMO) | ||
| Serum | Anti-adrenal cortex antibodies; Anti-endomysial antibodies (EMA); Anti-islet cell antibodies (ICA); Anti-neutrophil cytoplasmic antibodies - ANCA IIF; Anti-ovarian antibodies (AOA); Anti-steroid cell antibodies; Anti-testis antibodies | |
| Anti-acetylcholine receptor antibodies (AChR) | ||
| Anti-Saccharomyces IgA antibodies; Anti-Saccharomyces IgG antibodies; Anti-Saccharomyces cerevisiae antibodies (ASCA) | ||
| Anti-cardiac antibodies; Anti-keratin antibodies (AKA); Anti-liver-kidney microsomes antibodies (LKM); Anti-parietal cell antibodies; Anti-reticulin antibodies (RCA, ARA); Anti-smooth muscle antibodies (SMA); Anti-striated muscle antibodies | ||
| Anti-BP180; Anti-BP230; Anti-collagen VII; Anti-desmoglein-1 antibodies (DSG-1); Anti-desmoglein-3 antibodies (DSG-3); Anti-envoplakin | ||
| Anti-β2-glycoprotein-I antibodies | ||
| Anti-glutamic acid decarboxylase antibodies (GAD); Anti-islet tyrosine phosphatase2 (IA2) antibodies | ||
| Anti-cyclic citrullinated peptide antibodies (CCP) | ||
| Anti-cardiolipin antibodies (ACA); Anti-deamidated gliadin antibodies; Anti-glomerular basement membrane antibodies (anti-GBM); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase IgA antibodies (tTG) | ||
| Anti-CV2; Anti-EJ antibodies; Anti-Hu; Anti-Hu (ANNA-1); Anti-Jo-1 antibodies; Anti-Ku antibodies; Anti-Ma antibodies; Anti-Mi-2 antibodies; Anti-NOR 90 antibodies; Anti-NXP2 antibodies; Anti-OJ antibodies; Anti-PL-12 antibodies; Anti-PL-7 antibodies; Anti-PML antibodies; Anti-Pm/Scl antibodies; Anti-RNA polymerase III - RP11, RP155; Anti-RNA polymerase III antibodies (ARA, RNAP); Anti-Ri (ANNA-2); Anti-Ro antibodies; Anti-Ro-52 antibodies; Anti-SAE1 antibodies; Anti-SOX1; Anti-Scl-70 antibodies; Anti-Smith antibodies (Sm); Anti-Sp-100 antibodies; Anti-Yo (anti-PCA1); Anti-amphiphysin; Anti-centromere protein A antibodies (Cenp-A); Anti-centromere protein B antibodies (Cenp-B); Anti-fibrillarin antibodies; Anti-glycoprotein-210 antibodies (GP210); Anti-histone antibodies (AHA); Anti-liver cytosol antibodies (LC-1); Anti-liver-kidney microsomes type 1 (LKM1) antibodies; Anti-melanoma differentiation associated gene 5 antibodies (MDA5); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-myositis antibodies; Anti-nuclear antibodies (ANA); Anti-platelet derived growth factor (PDGF) receptor-α antibodies; Anti-platelet derived growth factor (PDGF) receptor-β antibodies; Anti-proliferating cell nuclear antigen (PCNA); Anti-ribonucleoprotein antibodies (RNP); Anti-ribosomal P protein antibodies; Anti-scleroderma antibodies; Anti-signal recognition particle antibodies (SRP); Anti-soluble liver antigen/liver-pancreas antibodies (SLA/LP); Anti-titin; Anti-transcription intermediary factor antibodies (TIF1); Anti-tyrosine hydroxylase antibodies (Th/To); Collapsin response mediator protein (CRMP) 5 antibodies | ||
| Anti-intercellular cement substance IgG antibodies; Anti-skin antibodies; Anti-skin basement membrane antibodies | ||
| Anti-Jo-1 antibodies; Anti-Ku antibodies; Anti-Mi-2 antibodies; Anti-Pm/Scl antibodies; Anti-Scl-70 antibodies; Anti-Smith antibodies (Sm); Anti-extractable nuclear antigen antibodies (ENA); Anti-proliferating cell nuclear antigen (PCNA); Anti-ribonucleoprotein antibodies (RNP); Anti-ribosomal P protein antibodies; Sjogrens syndrome antibodies A (SSA/Ro); Sjogrens syndrome antibodies B (SSB/La) | ||
| Anti-voltage gated calcium channel antibodies (VGCC) | ||
| Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Anti-double stranded DNA antibodies (dsDNA) | ||
| Immunopathology - Quantitation of complement proteins | Serum | CH50 |
| Immunopathology - Quantitative investigation and/or assessment of neutrophils | Blood | Adherence; Oxidative burst |
| Immunopathology - Single HLA antigen typing | Blood | HLA-B27 |
| HLA-B5701 | ||
| HLA-B5701 | ||
| Immunopathology - Tests of cellular immunity - Lymphocyte function tests | Blood | T-cell subsets; T-lymphocyte, B-lymphocyte and natural killer (TBNK) |
| Lymphocyte function; Proliferation by antigens; Proliferation by mitogens | ||
| Microbiology - Molecular biology - Quantitation of microbial nucleic acids | Plasma | Human immunodeficiency virus (HIV) RNA viral load; Human immunodeficiency virus type 1 (HIV-1) RNA |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Serum | Tetanus IgG antibody |
| Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies | ||
| Plasma; Serum | Human immunodeficiency virus (HIV) p24 antigen | |
| Molecular genetics - DNA extraction | Blood; Buccal swabs | DNA storage for future analyses; Viable DNA; Viable DNA for sequencing |
Microbiology
ISO 15189 (2012)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Molecular biology - Microbial genotyping by whole genome sequencing studies | Isolates | Bacteria; Mycobacteria (MTBC) |
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Bacterial isolates | Pathogenic identification |
| Pathogenic identification and antibiotic susceptibility | ||
| Carbapenem resistant Enterobacteriaceae (CRE); Carbapenem resistant Pseudomonas aeruginosa (CRP) | ||
| Blood | Bacteria; Pathogenic microorganisms | |
| Blood; Cerebrospinal fluid (CSF); Faeces; Fluids; General swabs; Operative specimens; Respiratory specimens; Tissues; Urine | Bacteria; Pathogenic microorganisms | |
| Bacteria; Pathogenic microorganisms | ||
| Blood; Cerebrospinal fluid (CSF); Fluids; General swabs; Operative specimens; Respiratory specimens; Tissues | Bacteria; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Pathogenic microorganisms | |
| Faeces | Clostridioides difficile toxin | |
| Urine | Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC); Pathogenic microorganisms; Red blood cell morphology | |
| Legionella antigen; Streptococcus pneumoniae antigen | ||
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Air; Spore strips | Bacterial growth - Sterility |
| Bacterial isolates | Bacterial organism identification - Carbapenem resistant Enterobacteriaceae (CRE); Bacterial organism identification - Extended spectrum β-lactamases (ESBL); Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA); Bacterial organism identification - Vancomycin-resistant Enterococcus (VRE); Mycobacteria identification | |
| Blood transfusion bags; Gastrointestinal endoscopes; Vascular catheter tips | Bacterial growth - Sterility | |
| Environmental swabs; MRO screening swabs | Yeast organism identification - Candida auris | |
| Environmental swabs; Medical devices; Waters | Bacterial organism identification - Carbapenem resistant Enterobacteriaceae (CRE); Bacterial organism identification - Extended spectrum β-lactamases (ESBL); Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA); Bacterial organism identification - Vancomycin-resistant Enterococcus (VRE); Mycobacteria identification | |
| Microbiology - Molecular biology - Bioinformatic analysis | DNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Amniotic fluid; Bacterial isolates; Blood; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Genital swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Respiratory specimens; Sputum; Sterile site; Tissues; Urine; Wound swabs | Bartonella henselae; Bordetella pertussis; Chlamydia trachomatis serovars L1, L2, L2a or L3 (LGV); Chlamydophila pneumoniae; Clostridioides difficile; Haemophilus ducreyi; Legionella longbeachae; Legionella pneumophila; Mycoplasma pneumoniae; Neisseria gonorrhoeae; Neisseria meningitidis; Streptococcus pneumoniae; Treponema pallidum |
| Anal swab; Cervical specimen; Endocervical swabs; Liquid based cytology specimens; Oropharyngeal swabs; Rectal swabs; Urine; Vaginal swabs | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Anal swab; Cervical swabs; Endocervical swabs; Oropharyngeal swabs; Rectal swabs; Urine; Vaginal swabs | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Bacterial isolates | Carbapenem resistant Enterobacteriaceae (CRE); Carbapenem resistant Pseudomonas aeruginosa (CRP); Vancomycin resistant Enterococci (VRE) vanA/vanB genes | |
| Enterobacteriaceae resistant gene IMP-4 like; Enterobacteriaceae resistant gene KPC; Enterobacteriaceae resistant gene OXA-48 like; Enterobacteriaceae resistant gene VIM; Enterobacteriaceae resistant gene NDM; Staphylococcus aureus (including MRSA) Panton-Valentine leukcocidin (PVL) gene; Carbapenem resistant Acinetobacter (CRAB); Carbapenem resistant Enterobacteriaceae (CRE); Carbapenem resistant Pseudomonas aeruginosa (CRP); Vancomycin resistant Enterococci (VRE) | ||
| Burkholderia cepacia complex | ||
| Pan-bacterial 16s | ||
| Bacterial isolates; Blood; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Genital swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Respiratory specimens; Sterile site; Tissues; Urine; Wound swabs | Bartonella henselae; Bordetella pertussis; Burkholderia cepacia complex; Campylobacter spp.; Chlamydia trachomatis; Chlamydia trachomatis serovars L1, L2, L2a or L3 (LGV); Clostridioides difficile; Haemophilus ducreyi; Mycoplasma pneumoniae; Neisseria gonorrhoeae; Neisseria meningitidis; Salmonella spp.; Shigella spp.; Streptococcus pneumoniae; Treponema pallidum; Vibrio cholerae; Vibrio parahaemolyticus; Yersinia enterocolitica; Methicillin resistant Staphylococcus aureus (MRSA); Pan-bacterial 16s | |
| Cerebrospinal fluid (CSF) | Escherichia coli K1; Haemophilus influenzae; Listeria monocytogenes; Neisseria meningitidis - Encapsulated; Streptococcus agalactiae (Streptococcus group B); Streptococcus pneumoniae | |
| Faeces | Campylobacter spp.; Salmonella spp.; Shigella spp.; Vibrio cholerae; Vibrio parahaemolyticus; Yersinia enterocolitica | |
| Genital swabs; Rectal swabs; Throat swabs; Urine | Moxifloxacin resistant Mycoplasma genitalium | |
| Genital swabs; Rectal swabs; Urine | Mycoplasma genitalium; Azithromycin resistant Mycoplasma genitalium; Macrolide resistant Mycoplasma genitalium | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (fungi) | Bacterial isolates; Bronchoalveolar lavage; Nasopharyngeal aspirate; Sputum | Pneumocystis jirovecii |
| Cerebrospinal fluid (CSF) | Cryptococcus gattii; Cryptococcus neoformans | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (helminth parasites) | Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue | Haycocknema perplexum |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Ascitic fluid; Bacterial isolates; Cerebrospinal fluid (CSF); Faeces; Gastrointestinal fluid; General swabs; Lymph node fluid; Paraffin embedded tissue; Pericardial fluid; Peritoneal fluid; Pleural fluid; Respiratory specimens; Sputum; Tissues | Mycobacterium tuberculosis complex; Mycobacterium rifampicin resistance rpoB |
| Ascitic fluid; Bacterial isolates; Cerebrospinal fluid (CSF); Gastrointestinal fluid; General swabs; Lymph node fluid; Paraffin embedded tissue; Pericardial fluid; Peritoneal fluid; Pleural fluid; Respiratory specimens; Sputum; Tissues | Mycobacterium tuberculosis complex | |
| Mycobacterium leprae; Mycobacterium tuberculosis complex; Mycobacterium ulcerans | ||
| Mycobacterium tuberculosis complex | ||
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Amniotic fluid; Blood; Bronchial washings; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Genital swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Respiratory specimens; Sputum; Sterile site; Tissues; Urine; Wound swabs | Toxoplasma gondii |
| Blood | Plasmodium falciparum; Plasmodium malariae; Plasmodium ovale; Plasmodium vivax | |
| Blood; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Genital swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Respiratory specimens; Sterile site; Tissues; Urine; Wound swabs | Toxoplasma gondii | |
| Faeces | Blastocystis spp.; Dientamoeba fragilis | |
| Cryptosporidium spp.; Entamoeba histolytica; Giardia intestinalis | ||
| Genital swabs; Urine | Trichomonas vaginalis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Aspirates; Lavage; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum; Throat swabs; Tissues; Washings | Adenovirus; Human metapneumovirus; Parainfluenza virus type 1/2/3/4; Rhinovirus |
| Blood; Bronchoalveolar lavage; Cerebrospinal fluid (CSF); Eye swabs; Faeces; Genital swabs; Isolates; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sterile site; Tissues; Urine | Adenovirus; BK virus; Cytomegalovirus (CMV); Enterovirus; Epstein-Barr virus; Herpes simplex virus (HSV); Human herpes virus type 6 (HHV6); Human parechovirus; John Cunningham virus (JC); Parvovirus B19; Varicella zoster virus (VZV) | |
| Bronchial lavage; Bronchial washings; Endotrachael aspirate; Nasal swabs; Nasopharyngeal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Bronchial washings; Bronchoalveolar lavage; Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Bronchoalveolar lavage; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Throat swabs | Adenovirus group E; Adenovirus group F; Human metapneumovirus; Influenza A virus; Influenza A virus H5; Influenza B virus; Influenza virus H1N1 - Swine; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV) | |
| Cadaveric donor; Plasma; Serum | Hepatitis B virus (HBV) DNA; Hepatitis C virus (HCV) viral RNA; Human immunodeficiency virus type 1 (HIV-1) RNA | |
| Cerebrospinal fluid (CSF) | Cytomegalovirus (CMV); Enterovirus; Herpes simplex virus 6; Herpes simplex virus type 1 (HSV1); Herpes simplex virus type 2 (HSV2); Human parechovirus; Varicella zoster virus (VZV) | |
| Cervical specimen | Human papilloma virus (HPV) | |
| Faeces | Norovirus | |
| Adenovirus F40; Adenovirus F41; Norovirus; Rotavirus | ||
| Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Nasal swabs; Nasopharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasopharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) | ||
| Nasopharyngeal swabs; Oropharyngeal swabs | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV); Rhinovirus; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Plasma | Cytomegalovirus (CMV); Hepatitis B virus (HBV) DNA | |
| Hepatitis C virus (HCV) genotypes 1-6 and subtypes | ||
| Microbiology - Molecular biology - Microbial DNA and/or RNA extraction | Blood; Bronchial washings; Bronchoalveolar lavage; Formalin-fixed paraffin-embedded (FFPE) tissues; Sputum; Tissues | Viable RNA |
| Purified bacterial isolates; Purified mycobacterial isolates | Viable DNA for sequencing | |
| Microbiology - Molecular biology - Microbial DNA and/or RNA sequencing | Extracted DNA | DNA sequence analysis |
| Microbiology - Molecular biology - Microbial genotyping | Isolates | Drug resistance Mycobacterium tuberculosis |
| Mycobacterium tuberculosis; Other microbes | ||
| Mycobacterium tuberculosis; Other microbes | ||
| Mycobacterium tuberculosis; Other microbes | ||
| Microbiology - Molecular biology - Quantitation of microbial nucleic acids | Blood | Adenovirus viral load |
| BK viral load; Epstein-Barr virus viral load | ||
| Plasma | Cytomegalovirus (CMV) viral load; Hepatitis B virus (HBV) viral load; Hepatitis C virus (HCV) viral load | |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Aspirates; Blood; Bone marrow; Cerebrospinal fluid (CSF); Faeces; Other body fluids; Respiratory specimens; Sputum; Tissues; Urine | Mycobacteria detection |
| Cerebrospinal fluid (CSF); General swabs; Other body fluids; Respiratory specimens; Sputum; Urine | Mycobacterium tuberculosis complex antigen | |
| Isolates | Mycobacteria identification | |
| Mycobacteria antibiotic susceptibility | ||
| Microbiology - Mycobacteriology - Tests for cell mediated immunity | Blood | Latent tuberculosis |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Blood; Cerebrospinal fluid (CSF); Fluids; General swabs; Hair; Nails; Respiratory swabs; Skin scrapings; Sputum; Tissues; Urine | Fungi isolation; Yeast isolation |
| Fungi detection; Yeast detection | ||
| Cerebrospinal fluid (CSF); Serum | Cryptococcus antigen | |
| Isolates | Fungi identification; Yeasts identification | |
| Yeast susceptibility | ||
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
| Genital swabs; Urine | Trichomonad | |
| Urine | Schistosoma spp. | |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Serum | Hydatid antibody |
| Plasma; Serum | Hepatitis C virus (HCV) | |
| Bordetella pertussis IgA; Bordetella pertussis IgG | ||
| Human T-lymphotropic virus type I/II (HTLV-I/II) | ||
| Hepatitis D virus (HDV) | ||
| Anti-streptolysin O (ASOT) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) antibody | ||
| Syphilis Treponema pallidum IgM antibody | ||
| Human T-lymphotropic virus type I/II (HTLV-I/II) | ||
| Brucella IgG antibody; Brucella IgM antibody | ||
| Serum | Parvovirus | |
| Mycoplasma spp. | ||
| Cytomegalovirus (CMV) activity index; Cytomegalovirus antibody (anti-CMV) IgG; Epstein-Barr virus nuclear antigen; Hepatitis B virus surface antigen (HBs Ag); Mumps virus; Rubella IgM antibody; Toxoplasma gondii IgM antibody | ||
| Barmah forest virus total antibody; Ross River virus | ||
| Syphilis Treponema pallidum antibody | ||
| Entamoeba histolytica | ||
| Measles IgG antibody; Mumps virus IgG antibody; Varicella zoster virus (VZV) IgG antibody | ||
| Herpes simplex virus (HSV) | ||
| Coxiella burnetii (Q-fever) IgA phase 1 antibody; Coxiella burnetii (Q-fever) IgA phase 2 antibody; Coxiella burnetii (Q-fever) IgG phase 1 antibody; Coxiella burnetii (Q-fever) IgG phase 2 antibody; Coxiella burnetii (Q-fever) IgM phase 1 antibody; Coxiella burnetii (Q-fever) IgM phase 2 antibody; Legionella spp. | ||
| Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus core antibody (anti-HBc) - IgG; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis C virus (HCV) | ||
| Dengue virus IgM antibody | ||
| Fluorescent Treponemal antibody | ||
| Aspergillus precipitins; Avian precipitins (bird fancier's disease) | ||
| Rubella IgG antibody; Syphilis Treponema pallidum antibody | ||
| Bartonella henselae IgG antibody | ||
| Coxiella burnetii (Q-fever) IgM phase 2 antibody | ||
| Coxiella burnetii (Q-fever) IgG phase 1 antibody; Coxiella burnetii (Q-fever) IgG phase 2 antibody | ||
| Human herpes virus type 6 (HHV6) IgM antibody | ||
| Schistosoma mansoni; Strongyloides spp. | ||
| Leptospira IgM antibody | ||
| Rickettsia spp. | ||
| Measles IgM antibody; Mumps virus IgM antibody; Varicella zoster virus IgM antibody | ||
| Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Rubella IgM antibody; Toxoplasma gondii IgG antibody; Toxoplasma gondii IgM antibody | ||
| Streptococcal anti-DNAse B (anti-streptodornase) antibody | ||
| Epstein-Barr virus viral capsid antigen | ||
| Chlamydia spp. |
Molecular Genetics
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Spinal muscular atrophy |
| Blood; Dried blood spots | Apolipoprotein E genotyping; Factor V Leiden; Nucleic acid analysis for specific variants | |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Dried blood spots | Apolipoprotein E genotyping; Factor V Leiden; Nucleic acid analysis for specific variants |
| Molecular genetics - DNA extraction | Amniotic fluid; Blood; Body fluids; Buccal swabs; Buffy coat; Formalin-fixed paraffin-embedded (FFPE) tissues; Hair; OraCollect; Saliva; Tissues; Urine | DNA storage for future analyses; Purified PCR product; Viable DNA; Viable DNA for sequencing |
| Cytology samples; Tissues | DNA storage for future analyses; Viable DNA | |
| Molecular genetics - DNA fragment size analysis | Blood; Fluorescent-labelled DNA sequencing reaction product; Tissues | DNA fragment size determination |
| Molecular genetics - DNA sequencing | Amniotic fluid; Blood; Extracted DNA; Fluorescent-labelled DNA sequencing reaction product; Purified PCR product; Tissues | DNA sequence analysis; DNA sequencing reaction purification step; Sequenced DNA; Sequenced DNA by Sanger sequencing |
| Molecular genetics - Estimation of risk of inheritance of an unknown mutation (Bayesian and linkage calculations) | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Fluids; Tissues | Cystic fibrosis; Estimation of risk; Uniparental disomy |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Amniotic fluid; Aspirates; Blood; Bone marrow; Chorionic villus; Dried blood spots; Fluids; Sputum; Tissues | Blood borne tumours; Chronic myeloid leukaemia (CML); Ewings sarcoma; Nucleic acid analysis for specific variants; Quantitative calculation of p210 positive BCR::ABL1 transcripts; Solid tumours |
| Tissues | Nucleic acid analysis for specific variants | |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Amniotic fluid; Aspirates; Blood; Bone marrow; Chorionic villus; Dried blood spots; Fluids; Fresh tissue; Sputum; Tissues | Blood borne tumours; Chronic myeloid leukaemia (CML); Ewings sarcoma; Quantitative calculation of p210 positive BCR::ABL1 transcripts; Solid tumours |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Whole exome sequencing for non-inherited (somatic) DNA/RNA changes | Blood; Bone marrow; Extracted DNA; Tissues | Blood borne tumours; Solid tumours |
| Molecular genetics - Heterozygous loci determinations | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Fluids; Tissues | Blood borne tumours; Cystic fibrosis; Deafness panel; Duchenne-Becker muscular dystrophy; Nucleic acid analysis for specific variants |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes | Amniotic fluid; Blood; Chorionic villus tissue; Extracted DNA | Spinal muscular atrophy |
| Amniotic fluid; Blood; Chorionic villus; Saliva; Tissues | Angelman syndrome; Breast cancer; Cystic fibrosis; Deafness; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Haemophilia A; Hereditary colorectal cancer; Hereditary non-syndromic deafness; Huntington's disease; Hyperparathyroidism-2; Inherited cancer syndromes; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Medium chain acyl-coenzyme A dehydrogenase (MCAD); Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia | |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Dried blood spots; Saliva; Tissues; Urine | Angelman syndrome; Breast cancer; Cystic fibrosis; Deafness; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Gaucher disease; Glutaric acidemia; Haemophilia A; Hereditary non-syndromic deafness; Huntington's disease; Hyperparathyroidism-2; Inherited cancer syndromes; Kennedy's disease (spinal and bulbar muscular atrophy); Medical exome; Medium chain acyl-coenzyme A dehydrogenase (MCAD); Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Nucleic acid analysis for unknown variants; Paragangliomas; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia |
| Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Fragile X; Myotonic dystrophy | |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Breast cancer; Hereditary colorectal cancer; Hereditary diffuse gastric cancer; Hereditary pancreatitis; Inherited cancer syndromes | |
| Fragile X | ||
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Whole exome sequencing studies for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Copy number variation (CNV); Duchenne-Becker muscular dystrophy; Inherited disorders; Severe combined immunodeficiency disease (SCID) |
| Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Whole genome sequencing studies for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Copy number variation (CNV); Inherited disorders; Paediatric monogenic rare disorders |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Dried blood spots; Fluids; Saliva; Tissues | Angelman syndrome; Birt-Hogg-Dubé syndrome; Blood borne tumours; Breast cancer; Cystic fibrosis; Deafness; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Haemophilia A; Hereditary non-syndromic deafness; Huntington's disease; Hyperparathyroidism-2; Inherited cancer syndromes; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia |
| Amniotic fluid; Blood; Chorionic villus tissue; Extracted DNA | Spinal muscular atrophy | |
| Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Fragile X; Myotonic dystrophy | |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Dried blood spots; Fluids; Saliva; Tissues | Angelman syndrome; Breast cancer; Cystic fibrosis; Deafness; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Haemophilia A; Hereditary non-syndromic deafness; Huntington's disease; Hyperparathyroidism-2; Inherited cancer syndromes; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Medium chain acyl-coenzyme A dehydrogenase (MCAD); Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Nucleic acid analysis for unknown variants; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Breast cancer; Hereditary colorectal cancer; Hereditary diffuse gastric cancer; Hereditary pancreatitis; Inherited cancer syndromes | ||
| Molecular genetics - Mitochondrial investigation for heteroplasmy of constitutional genetic abnormalities - Diagnostic testing | Blood; Dried blood spots; Liver; Muscle; Saliva; Urine | Mitochondrial DNA analysis for specific or unknown variants |
| Molecular genetics - Mitochondrial investigation for heteroplasmy of constitutional genetic variants - Carrier testing | Blood; Dried blood spots; Liver; Muscle; Saliva; Urine | Mitochondrial DNA analysis for specific or known variants |
| Molecular genetics - Predictive genetic testing | Blood | BRCA mutation screening; BRCA presymptomatic testing; Nucleic acid analysis for specific variants (other than BRCA) |
| Molecular genetics - Predictive genetic testing - Targeted genes | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Dried blood spots; Fluids; Saliva; Tissues | Angelman syndrome; Breast cancer; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Galactosemia; Haemophilia A; Haemophilia B; Huntington's disease; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Medium chain acyl-coenzyme A dehydrogenase (MCAD) deficiency; Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia |
| Amniotic fluid; Blood; Chorionic villus tissue; Extracted DNA | Fragile X; Myotonic dystrophy | |
| Spinal muscular atrophy | ||
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Molecular genetics - Predictive genetic testing - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Bone marrow; Chorionic villus; Dried blood spots; Saliva; Tissues; Urine | Angelman syndrome; Breast cancer; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Galactosemia; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Medium chain acyl-coenzyme A dehydrogenase (MCAD) deficiency; Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Prader-Willi syndrome; Spinocerebellar ataxia; α-Thalassaemia; α1-Antitrypsin; β-Thalassaemia |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Molecular genetics - Predictive genetic testing - Whole genome sequencing studies for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Copy number variation (CNV); Inherited disorders; Paediatric monogenic rare disorders |
| Molecular genetics - Predictive mitochondrial genetic testing | Amniotic fluid; Blood; Chorionic villus; Dried blood spots; Muscle; Saliva | Mitochondrial DNA analysis for specific or known variants |
| Molecular genetics - RNA extraction | Amniotic fluid; Blood; Buffy coat; Formalin-fixed paraffin-embedded (FFPE) tissues; OraCollect; Saliva; Tissues | Purified PCR product; RNA storage for future analyses; Viable RNA; Viable RNA for sequencing |
| Molecular genetics - RNA sequencing | Extracted RNA | Sequenced RNA; Sequenced RNA by Sanger sequencing |
| Molecular genetics - Screening for an unknown mutation - Targeted genes | Amniotic fluid; Blood; Chorionic villus; Dried blood spots | Angelman syndrome; Blood borne tumours; Breast cancer; Cystic fibrosis; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Hereditary non-syndromic deafness; Huntington's disease; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Nucleic acid analysis for unknown variants; Prader-Willi syndrome; Solid tumours; Spinocerebellar ataxia |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X; Myotonic dystrophy | |
| Fragile X | ||
| Molecular genetics - Screening for an unknown mutation - Targeted panels for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus | Angelman syndrome; Breast cancer; Cystic fibrosis; Dentatorubral-pallidoluysian atrophy (Naito-Oyanagi disease); Duchenne-Becker muscular dystrophy; Fragile X; Friedreich's ataxia (FRDA, FA); Galactosemia; Hereditary non-syndromic deafness; Kennedy's disease (spinal and bulbar muscular atrophy); Laminopathies; Mitochondrial disorders; Multiple endocrine neoplasia type 1 (MEN1); Myotonic dystrophy; Nucleic acid analysis for unknown variants; Prader-Willi syndrome; Spinocerebellar ataxia |
| Amniotic fluid; Chorionic villus | Fragile X | |
| Blood | Fragile X | |
| Molecular genetics - Screening for an unknown mutation - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood | Quantitative calculation of p210 positive BCR::ABL1 transcripts |
| Blood; Bone marrow; Dried blood spots; Fluids; Tissues | Blood borne tumours; Nucleic acid analysis for unknown variants; Quantitative calculation of p210 positive BCR::ABL1 transcripts; Solid tumours | |
| Molecular genetics - Screening for an unknown mutation - Whole exome sequencing studies for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Copy number variation (CNV); Duchenne-Becker muscular dystrophy; Inherited disorders; Severe combined immunodeficiency disease (SCID) |
| Molecular genetics - Screening for an unknown mutation - Whole genome sequencing studies for inherited (germline) DNA/RNA changes | Amniotic fluid; Blood; Chorionic villus; Extracted DNA | Copy number variation (CNV); Inherited disorders; Paediatric monogenic rare disorders |
| Molecular genetics/Cytogenetics - Bioinformatic analysis | DNA sequences; RNA sequences | Primary analysis - Conversion of instrument file to FASTQ or FASTA file; Secondary analysis - Alignment and variant calling; Tertiary analysis - Data annotation and interpretation |
POCT – At ward locations by laboratory staff
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | International normalised ratio (INR); Prothrombin time (PT) |
| Haematology - Limited blood examination | Blood | Haemoglobin (Hb) |
POCT – Birthing Suite
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; Total carbon dioxide (TCO2); pH |
POCT – Department of Emergency Medicine
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
POCT – Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
| Anion gap; Base excess; Bicarbonate; Calcium - Ionised; Chloride; Creatinine; Glucose; Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; Total carbon dioxide (TCO2); Urea; pH | ||
| Haematology - Full blood examination | Blood | Haematocrit (packed cell volume, PCV); Haemoglobin (Hb) |
POCT – L4 Operating Theatre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Haemoglobin F (HbF); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; p50; pH |
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Kaolin clotting time |
POCT – L5 Operating Theatre
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; Total carbon dioxide (TCO2); pH |
POCT – Neonatal Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Anion gap; Base excess; Bicarbonate; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Haemoglobin F (HbF); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; p50; pH |
POCT – Neonatal Retrieval Emergency Service
ISO 15189 (2012)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Base excess; Bicarbonate; Calcium - Ionised; Glucose; Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Lactate; Oxygen saturation (sO2); Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; Total carbon dioxide (TCO2); pH |
POCT – Positronic Emission Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Blood | Anion gap; Calcium - Ionised; Chloride; Creatinine; Glucose; Potassium; Sodium; Total carbon dioxide (TCO2); Urea |
| Haematology - Full blood examination | Blood | Haematocrit (packed cell volume, PCV); Haemoglobin (Hb) |
POCT – Special Care Nursery
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Anion gap; Base excess; Bicarbonate; Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Haemoglobin F (HbF); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; p50; pH |
POCT – STARS
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
POCT – Thoracic Medicine
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Pleural fluid | pH |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Methaemoglobin (MetHb); Oxygen saturation (sO2); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Transfusion
ISO 15189 (2022)
Human Pathology
Medicare expiry date
05 Jul 2028
Last Activity Date
01 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Immunohaematology - Blood group antibody detection | Blood | Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood; Cord blood | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Blood; Cord blood | Direct antiglobulin test (DAT, direct Coombs test) | |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Antibody titration |
| Red blood cell phenotyping | ||
| Other blood group antibodies; Rh | ||
| Antibody elution | ||
| Immunohaematology - Investigation of blood transfusion reactions | Blood products | Antibodies |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood; Blood products | Issue and release of blood and blood products for transfusion |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2639
Site No.
2632
Print date
26 Nov 2024
END OF SCOPE